TW420659B - Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical, as inhibitors of the cellular Na+/H+ exchange or as a diagnostic, and pharmaceutical containing them - Google Patents
Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical, as inhibitors of the cellular Na+/H+ exchange or as a diagnostic, and pharmaceutical containing them Download PDFInfo
- Publication number
- TW420659B TW420659B TW083102858A TW83102858A TW420659B TW 420659 B TW420659 B TW 420659B TW 083102858 A TW083102858 A TW 083102858A TW 83102858 A TW83102858 A TW 83102858A TW 420659 B TW420659 B TW 420659B
- Authority
- TW
- Taiwan
- Prior art keywords
- guanidine
- formula
- benzamidine
- patent application
- item
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract 14
- 238000000034 method Methods 0.000 title claims abstract 6
- 239000003112 inhibitor Substances 0.000 title claims 3
- 230000001413 cellular effect Effects 0.000 title claims 2
- AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical class NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims abstract 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- CSEJFCCVLMOPDR-UHFFFAOYSA-N NC(N)=N.NC(=N)C1=CC=CC=C1 Chemical compound NC(N)=N.NC(=N)C1=CC=CC=C1 CSEJFCCVLMOPDR-UHFFFAOYSA-N 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 10
- -1 4-methyl benzamidine guanidine Chemical compound 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 230000002079 cooperative effect Effects 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 239000000047 product Substances 0.000 claims 4
- 230000006793 arrhythmia Effects 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960000789 guanidine hydrochloride Drugs 0.000 claims 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 208000006752 brain edema Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000001788 irregular Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 238000010422 painting Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000033764 rhythmic process Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- VPVFRBVISRPGTF-UHFFFAOYSA-N 1-phenyl-1-pyridin-2-ylguanidine Chemical compound C1(=CC=CC=C1)N(C(=N)N)C1=NC=CC=C1 VPVFRBVISRPGTF-UHFFFAOYSA-N 0.000 claims 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims 1
- PUXHWHMUFJELKM-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=C(N)C=C1 PUXHWHMUFJELKM-UHFFFAOYSA-N 0.000 claims 1
- CYYQVFZVCJFKES-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]guanidine Chemical compound NC(N)=NCC1=CC=C(Cl)C=C1 CYYQVFZVCJFKES-UHFFFAOYSA-N 0.000 claims 1
- XRCSYMVDLYGKTE-UHFFFAOYSA-N 3-methylbenzenecarboximidamide Chemical compound CC1=CC=CC(C(N)=N)=C1 XRCSYMVDLYGKTE-UHFFFAOYSA-N 0.000 claims 1
- 102000003669 Antiporters Human genes 0.000 claims 1
- 108090000084 Antiporters Proteins 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 241000282421 Canidae Species 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 208000014174 Oesophageal disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001201 calcium accumulation Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000028299 esophageal disease Diseases 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 210000004211 gastric acid Anatomy 0.000 claims 1
- 230000027119 gastric acid secretion Effects 0.000 claims 1
- 238000007429 general method Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 229960004198 guanidine Drugs 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XEBPBJPZBUSUEO-UHFFFAOYSA-N n-(diaminomethylidene)formamide Chemical compound NC(=N)NC=O XEBPBJPZBUSUEO-UHFFFAOYSA-N 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- WAJUCMNAGKFHLB-UHFFFAOYSA-N phenylarsinic acid Chemical compound O[AsH](=O)C1=CC=CC=C1 WAJUCMNAGKFHLB-UHFFFAOYSA-N 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 abstract 1
- JBUZPXALMCPEIO-UHFFFAOYSA-N 4-chloro-n-(diaminomethylidene)benzamide Chemical compound NC(=N)NC(=O)C1=CC=C(Cl)C=C1 JBUZPXALMCPEIO-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- ZYBAROQWZRYRQL-UHFFFAOYSA-N n-(diaminomethylidene)-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC(N)=N)C=C1 ZYBAROQWZRYRQL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4305250 | 1993-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW420659B true TW420659B (en) | 2001-02-01 |
Family
ID=6480943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW083102858A TW420659B (en) | 1993-02-20 | 1994-04-01 | Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical, as inhibitors of the cellular Na+/H+ exchange or as a diagnostic, and pharmaceutical containing them |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5866610A (enExample) |
| EP (1) | EP0612723B1 (enExample) |
| JP (2) | JP3554352B2 (enExample) |
| AT (1) | ATE157351T1 (enExample) |
| AU (1) | AU668265B2 (enExample) |
| CA (1) | CA2115967A1 (enExample) |
| DE (1) | DE59403818D1 (enExample) |
| DK (1) | DK0612723T3 (enExample) |
| ES (1) | ES2107698T3 (enExample) |
| FI (1) | FI114467B (enExample) |
| GR (1) | GR3024855T3 (enExample) |
| HU (1) | HU218915B (enExample) |
| IL (1) | IL108697A (enExample) |
| NO (1) | NO300322B1 (enExample) |
| NZ (1) | NZ250919A (enExample) |
| TW (1) | TW420659B (enExample) |
| ZA (1) | ZA941119B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4318756A1 (de) * | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4421536A1 (de) * | 1994-06-20 | 1995-12-21 | Hoechst Ag | Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4421495A1 (de) * | 1994-06-20 | 1995-12-21 | Merck Patent Gmbh | Heterocyclyloxy-benzoylguanidine |
| IL114670A0 (en) * | 1994-08-05 | 1995-11-27 | Fujisawa Pharmaceutical Co | Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4430213A1 (de) * | 1994-08-28 | 1996-02-29 | Merck Patent Gmbh | Arylbenzoylguanidine |
| DE4430916A1 (de) * | 1994-08-31 | 1996-03-07 | Merck Patent Gmbh | Alkyl-benzoylguanidin-Derivate |
| DE4432101A1 (de) * | 1994-09-09 | 1996-03-14 | Hoechst Ag | Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4432106A1 (de) * | 1994-09-09 | 1996-03-14 | Hoechst Ag | Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung |
| DE4432105A1 (de) * | 1994-09-09 | 1996-03-14 | Hoechst Ag | Fluoro-alkyl/alkenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4441880A1 (de) * | 1994-11-24 | 1996-05-30 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19502644A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | 4-Amino-benzoylguanidin-Derivate |
| DE19517848A1 (de) * | 1995-05-16 | 1996-11-21 | Merck Patent Gmbh | Fluorhaltige Benzoylguanidine |
| DE19518073A1 (de) * | 1995-05-17 | 1996-11-21 | Hoechst Ag | Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19518796A1 (de) * | 1995-05-22 | 1996-11-28 | Hoechst Ag | Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
| US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| DE19526381A1 (de) * | 1995-07-19 | 1997-01-23 | Hoechst Ag | 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| EP0765867A1 (de) * | 1995-09-27 | 1997-04-02 | Hoechst Aktiengesellschaft | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19540995A1 (de) * | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19542306A1 (de) * | 1995-11-14 | 1997-05-15 | Hoechst Ag | Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PL316439A1 (en) * | 1995-11-20 | 1997-05-26 | Hoechst Ag | Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such |
| DE19546736A1 (de) * | 1995-12-14 | 1997-06-19 | Hoechst Ag | Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate |
| WO1997027183A1 (en) * | 1996-01-26 | 1997-07-31 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
| DE19606509A1 (de) * | 1996-02-22 | 1997-08-28 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19608161A1 (de) | 1996-03-04 | 1997-09-11 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19622222A1 (de) * | 1996-06-03 | 1997-12-04 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide |
| DE19622370A1 (de) * | 1996-06-04 | 1997-12-11 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| WO2001036351A2 (en) * | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
| US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| US6677479B2 (en) | 2001-11-13 | 2004-01-13 | Clariant Finance Lbvi Limited | Substituted fluoroaromatics, process for preparing them and their use |
| US7393934B2 (en) | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7375138B2 (en) | 2002-05-18 | 2008-05-20 | Sanofi-Aventis Deutschland Gmbh | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them |
| FR2840302B1 (fr) * | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| US6878748B2 (en) | 2002-06-13 | 2005-04-12 | Aventis Pharma Deutschland Gmbh | Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| WO2005105841A2 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| WO2013016571A1 (en) | 2011-07-28 | 2013-01-31 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
| RU2015107019A (ru) | 2012-08-21 | 2016-10-10 | Эрделикс Инк. | Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| CN105392483B (zh) | 2013-04-12 | 2019-03-15 | 阿德利克斯公司 | 用于抑制磷酸盐转运的nhe3结合化合物和方法 |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| WO2018058109A1 (en) | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
| CN111386279A (zh) | 2017-08-04 | 2020-07-07 | 阿德利克斯股份有限公司 | 用于治疗高钾血症的甘草次酸衍生物 |
| JP7735185B2 (ja) | 2019-02-07 | 2025-09-08 | アルデリックス， インコーポレイテッド | 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体 |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| WO2021222752A1 (en) | 2020-05-01 | 2021-11-04 | Harbor Medtech, Inc. | Port-accessible multidirectional reinforced minimally invasive collagen device for soft tissue repair |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780027A (en) * | 1970-04-29 | 1973-12-18 | Merck & Co Inc | Anthranilic acid derivatives |
| PH12016A (en) * | 1972-09-22 | 1978-10-06 | Rorer Inc William H | Amidinoureas |
| US4251545A (en) * | 1979-09-19 | 1981-02-17 | Gaf Corporation | Fungicidal process using 1-(alkoxyaroyl)guanidines |
| US4544670A (en) * | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
| DE3502629A1 (de) * | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Phenoxybenzoesaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz |
| DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
| EP0556674B1 (de) * | 1992-02-15 | 1996-06-19 | Hoechst Aktiengesellschaft | 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen |
| CZ284456B6 (cs) * | 1992-02-15 | 1998-12-16 | Hoechst Aktiengesellschaft | Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje |
| ES2100435T3 (es) * | 1992-12-16 | 1997-06-16 | Hoechst Ag | Aminobenzoilguanidinas 3,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene. |
| DE4318756A1 (de) * | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
1994
- 1994-02-16 DE DE59403818T patent/DE59403818D1/de not_active Expired - Lifetime
- 1994-02-16 DK DK94102322.8T patent/DK0612723T3/da active
- 1994-02-16 AT AT94102322T patent/ATE157351T1/de not_active IP Right Cessation
- 1994-02-16 EP EP94102322A patent/EP0612723B1/de not_active Expired - Lifetime
- 1994-02-16 ES ES94102322T patent/ES2107698T3/es not_active Expired - Lifetime
- 1994-02-17 IL IL10869794A patent/IL108697A/xx not_active IP Right Cessation
- 1994-02-17 FI FI940756A patent/FI114467B/fi active IP Right Grant
- 1994-02-18 NO NO940563A patent/NO300322B1/no unknown
- 1994-02-18 NZ NZ250919A patent/NZ250919A/en unknown
- 1994-02-18 ZA ZA941119A patent/ZA941119B/xx unknown
- 1994-02-18 HU HU9400466A patent/HU218915B/hu unknown
- 1994-02-18 CA CA002115967A patent/CA2115967A1/en not_active Abandoned
- 1994-02-18 AU AU55229/94A patent/AU668265B2/en not_active Ceased
- 1994-02-18 JP JP02076294A patent/JP3554352B2/ja not_active Expired - Fee Related
- 1994-04-01 TW TW083102858A patent/TW420659B/zh active
-
1996
- 1996-07-18 US US08/683,141 patent/US5866610A/en not_active Expired - Lifetime
-
1997
- 1997-09-24 GR GR970402499T patent/GR3024855T3/el unknown
-
2004
- 2004-03-24 JP JP2004087016A patent/JP3806431B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5866610A (en) | 1999-02-02 |
| HUT70535A (en) | 1995-10-30 |
| GR3024855T3 (en) | 1998-01-30 |
| FI940756A0 (fi) | 1994-02-17 |
| AU668265B2 (en) | 1996-04-26 |
| JP3806431B2 (ja) | 2006-08-09 |
| NZ250919A (en) | 1996-01-26 |
| EP0612723B1 (de) | 1997-08-27 |
| NO940563D0 (no) | 1994-02-18 |
| JPH06256291A (ja) | 1994-09-13 |
| JP2004189755A (ja) | 2004-07-08 |
| ZA941119B (en) | 1994-08-30 |
| NO300322B1 (no) | 1997-05-12 |
| DE59403818D1 (de) | 1997-10-02 |
| FI114467B (fi) | 2004-10-29 |
| AU5522994A (en) | 1994-08-25 |
| JP3554352B2 (ja) | 2004-08-18 |
| IL108697A0 (en) | 1994-05-30 |
| NO940563L (enExample) | 1994-08-22 |
| HU218915B (hu) | 2000-12-28 |
| ES2107698T3 (es) | 1997-12-01 |
| IL108697A (en) | 2000-07-16 |
| EP0612723A1 (de) | 1994-08-31 |
| ATE157351T1 (de) | 1997-09-15 |
| DK0612723T3 (da) | 1998-03-30 |
| HU9400466D0 (en) | 1994-05-30 |
| FI940756L (fi) | 1994-08-21 |
| CA2115967A1 (en) | 1994-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW486474B (en) | Prodrugs of aspartyl protease inhibitors | |
| US20210206774A1 (en) | Molecular containers and methods of making and using same | |
| TWI242005B (en) | Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | |
| RU2293078C2 (ru) | Соединения дибензиламина, фармацевтическая композиция и терапевтический или профилактический агент на их основе, способ лечения или профилактики гиперлипидемии или артериосклероза | |
| TW384281B (en) | 3,5-substituted aminobenzoylguanidines, process for their preparation and pharmaceutical compositions containing them | |
| JP3806431B2 (ja) | 置換されたベンゾイルグアニジンおよびそれらの製法 | |
| EP2404895A1 (en) | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | |
| CN103957710B (zh) | 用于治疗粘膜炎的化合物 | |
| JPH07121895B2 (ja) | アシル‐ＣｏＡ：コレステロールアシル転移酵素の阻害剤としての飽和脂肪酸アミド | |
| TW555738B (en) | Substituted benzamidines, their preparation and the pharmaceutical compounds for use as LTB4 antagonists containing the same | |
| TW415936B (en) | Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
| JP2007522135A (ja) | ニトロキシル前駆化合物および使用方法 | |
| JP2012031170A (ja) | ペプチダーゼエフェクターとしての医薬用途のための新規化合物 | |
| TW419455B (en) | Amino acid-substituted benzoylguanidine, a process for their preparation, and their pharmaceutical composition for use in cardiovascular treatment or diagnosis | |
| KR20110137941A (ko) | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물 | |
| WO2012053787A2 (ko) | Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 | |
| US20140128418A1 (en) | Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same | |
| CA2262997C (en) | Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells | |
| JPH1081664A (ja) | 置換された２−ナフトイルグアニジン、その製法、医薬または診断剤としてのその使用およびそれを含有する医薬 | |
| TW565559B (en) | Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them | |
| US5472981A (en) | Method of synthesis and novel compounds for pharmaceutical uses | |
| US20220089521A1 (en) | Ethylenediamine compound and use thereof | |
| TW438786B (en) | Novel benzothiazole derivatives | |
| US20170157135A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
| TWI240718B (en) | Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent |